1q21.3 amplification modulates therapy sensitivity in Triple-Negative Breast Cancer
Chirravuri Venkata, R.; Ghersi, D.; Ganti, A. K.; Lakshmanan, I.; Chaudhary, S.; Batra, S. K.; Nasser, M. W.
Show abstract
The contrast in therapy sensitivity and response across triple negative breast cancer (TNBC) patients suggest underlying genotypic heterogeneity. Using publicly available data, we found significant associations between DNA-level copy number alterations of 1q21.3 locus and therapy sensitivity. We show that in spite of their aggressive nature, 1q21.3 amplified tumors are more responsive to commonly used cytotoxic therapies, highlighting the relevance of 1q21.3 copy number status as a genetic marker for risk stratification, therapy selection and response.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.